Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M7,652Revenue $M1,054Net Margin (%)5.6Z-Score3.6
Enterprise Value $M8,688EPS $-0.3Operating Margin %10.5F-Score5
P/E(ttm))124Cash Flow Per Share $2.2Pre-tax Margin (%)5.7Higher ROA y-yY
Price/Book4.910-y EBITDA Growth Rate %0Quick Ratio3.3Cash flow > EarningsY
Price/Sales7.15-y EBITDA Growth Rate %-24.1Current Ratio3.5Lower Leverage y-yY
Price/Cash Flow18.6y-y EBITDA Growth Rate %115ROA % (ttm)2.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)4.5Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M76.3ROI % (ttm)5.6Gross Margin Increase y-yN

Gurus Latest Trades with CBST

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CBSTVanguard Health Care Fund 2014-09-30 Add0.09%$60.5 - $70.58
($65.63)
$ 100.2953%Add 34.74%1,977,342
CBSTKen Fisher 2014-06-30 Buy 0.01%$61.66 - $74.27
($67.99)
$ 100.2948%New holding, 36450 sh.36,450
CBSTLee Ainslie 2014-06-30 Sold Out -1.8%$61.66 - $74.27
($67.99)
$ 100.2948%Sold Out0
CBSTGeorge Soros 2014-06-30 Sold Out -0.04%$61.66 - $74.27
($67.99)
$ 100.2948%Sold Out0
CBSTLee Ainslie 2014-03-31 Buy 1.8%$67.2 - $81.23
($74.39)
$ 100.2935%New holding, 1739818 sh.1,739,818
CBSTAndreas Halvorsen 2014-03-31 Sold Out -0.24%$67.2 - $81.23
($74.39)
$ 100.2935%Sold Out0
CBSTGeorge Soros 2014-03-31 Reduce-0.06%$67.2 - $81.23
($74.39)
$ 100.2935%Reduce -65.4%50,000
CBSTAndreas Halvorsen 2013-12-31 Add0.05%$61.59 - $70.76
($64.66)
$ 100.2955%Add 24.72%741,700
CBSTJohn Burbank 2013-12-31 Sold Out -0.42%$61.59 - $70.76
($64.66)
$ 100.2955%Sold Out0
CBSTJoel Greenblatt 2013-12-31 Sold Out -0.05%$61.59 - $70.76
($64.66)
$ 100.2955%Sold Out0
CBSTJohn Burbank 2013-09-30 Buy 0.42%$51.58 - $66.54
($60.56)
$ 100.2966%New holding, 202451 sh.202,451
CBSTAndreas Halvorsen 2013-09-30 Buy 0.21%$51.58 - $66.54
($60.56)
$ 100.2966%New holding, 594704 sh.594,704
CBSTMichael Price 2013-09-30 Sold Out -1.2%$51.58 - $66.54
($60.56)
$ 100.2966%Sold Out0
CBSTGeorge Soros 2013-06-30 Buy 0.09%$44.66 - $56.11
($49.15)
$ 100.29104%New holding, 175000 sh.175,000
CBSTJohn Hussman 2013-03-31 Sold Out -0.75%$40.78 - $48.06
($44.18)
$ 100.29127%Sold Out0
CBSTJoel Greenblatt 2013-03-31 Reduce-0.18%$40.78 - $48.06
($44.18)
$ 100.29127%Reduce -72.24%28,134
CBSTJoel Greenblatt 2012-12-31 Buy 0.25%$39.17 - $48.63
($43.07)
$ 100.29133%New holding, 101334 sh.101,334
CBSTJoel Greenblatt 2012-09-30 Sold Out -0.12%$37.91 - $49.83
($43.89)
$ 100.29128%Sold Out0
CBSTJoel Greenblatt 2012-06-30 Add0.04%$38.38 - $44.07
($40.88)
$ 100.29145%Add 49.02%41,492
CBSTJohn Hussman 2012-03-31 Add0.18%$38.77 - $44.72
($38.64)
$ 100.29160%Add 47.16%674,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CBST is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
CBST Vanguard Health Care Fund 2014-09-301,977,3422.590.33+34.74%
CBST Ken Fisher 2014-09-3034,7750.050-4.6%
Premium Most recent portfolio changes are included for Premium Members only!


CBST: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-10-01Sell48,125$65.3953.65view
STEA GREGORYSVP, Commercial Operations 2014-08-19Sell38,326$65.8852.5view
TOMSICEK MICHAEL JOHNSVP & CFO 2014-08-18Sell409$63.6857.77view
PEREZ ROBERT JPresident & COO 2014-08-18Sell1,003$63.6857.77view
Hutson Nancy JDirector 2014-08-18Sell9,000$6554.57view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-07-28Sell40,625$61.5763.18view
PEREZ ROBERT JPresident & COO 2014-05-15Sell1,518$67.548.84view
STEA GREGORYSVP, Commercial Operations 2014-05-15Sell875$67.548.84view
GILMAN STEVEN CEVP & Chief Scientific Officer 2014-05-15Sell16,340$67.8248.14view
BONNEY MICHAEL WCEO 2014-05-15Sell3,036$67.548.84view

Press Releases about CBST :

Quarterly/Annual Reports about CBST:

News about CBST:

Articles On GuruFocus.com
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Forest Laboratories Is an Option for Wealthy Investors Who Could Afford to Pay a High Premium Apr 23 2014 
Michael Price’s Top Sells – 11 Gurus Exit SFD Nov 19 2013 
Magic Formula Formulator Joel Greenblatt’s Top 5 New Stock Picks Feb 14 2013 
5 Healthcare Stocks to Consider in 2012 Mar 21 2012 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceuticals Inc. Reports Operating Results (10-Q) Apr 29 2010 
Weekly CEO Sells Highlight: Saba Software Inc, Cubist Pharmaceuticals Inc, Polo Ralph Lauren Corp, P Apr 25 2010 
Cubist Pharmaceuticals Inc. (CBST) President and CEO Michael W Bonney sells 184,548 Shares Apr 23 2010 


More From Other Websites
Merck Finally Gets Some Good News on Cubist Dec 22 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 22 2014
Approval of new antibiotic by Cubist to help in $100 trillion global fight Dec 22 2014
5:45 am Cubist Pharma announces FDA approval of new antibiotic ZERBAXA Dec 22 2014
[$$] FDA Approves Cubist's Experimental Antibiotic Zerbaxa Dec 19 2014
FDA Approves Second Cubist Antibiotic Of 2014 Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated... Dec 19 2014
FDA approves Cubists' drug for antibiotic-resistant bacteria Dec 19 2014
CUBIST PHARMACEUTICALS INC Files SEC form 8-K, Temporary Suspension of Trading Under Registrant's... Dec 19 2014
Merck Begins Tender Offer to Acquire Cubist Dec 19 2014
$100 trillion Superbugs threat Dec 18 2014
Tetraphase Jumps As 'Superbug' Drug Scores In Trial Dec 18 2014
Cubist Pharma downgraded by UBS Dec 17 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist... Dec 15 2014
Charting the Market Dec 13 2014
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist... Dec 12 2014
CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of... Dec 12 2014
CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Dec 11 2014
Lifshitz & Miller Law Firm Announces Investigation of Actuate Corporation, Albany Molecular Research... Dec 11 2014

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK